Acute leukaemias, especially acute myelogenous leukaemia & acute lymphoblastic leukaemia. It is also used in the treatment of chronic granulocytic leukaemia.

Pregnancy, lactation, prior resistance to drug.

Myelosupression, cytopenia, hyperuricaemia, nausea, vomiting, anorexia & stomatitis.

Myelosuppression is preduced by thioguanine. Evaluation of haemoglobin concentration or haematocrit, total white blood cell count, differential count and platelet count is necessary during the therapy. When used in combination with other drugs whose primary toxicity is myelosuppression, life-threatening infections and bleeding have been observed as a consequences of thioguanine induced granulocytopenia and thrombocytopenia.

Complete cross-resistance between mercaptopurine and thioguanine. Exercise caution during long-term continuous therapy with busulfan.

Exact dose and duration of administration will depend on the nature and dosage of other cytotoxic drugs given in conjunction. Induction therapy : 100-200mg / sq. m. body surface area / day on a single or twice daily dosing regimen over a period of 5-20 days.

40mg tablet,  25 tablets per box.

  
*  for the use of a registered Medical practitioner or a Hospital or a Laboratory only.

[Go Back to the Export product list]

Disclaimer : This guide is provided for information purposes only, and for use of a registered medical practitioner or a hospital or a laboratory only. The authors, webmaster, or respective references / links are no way responsible for the content of the information. Although a concerted effort has been made to ensure the validity of the information contained in this document, we give no assurance for the accuracy of the information in this documents.